e-learning
resources
Milan 2017
Sunday, 10.09.2017
Prognostic factors and outcomes in pulmonary embolism
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Half - dose of recombinant tissue-type plasminogen activator in the treatment of acute pulmonary embolism: long term outcomes
H. Oflaz Hezer (ANKARA, Turkey)
Source:
International Congress 2017 – Prognostic factors and outcomes in pulmonary embolism
Session:
Prognostic factors and outcomes in pulmonary embolism
Session type:
Poster Discussion
Number:
565
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
H. Oflaz Hezer (ANKARA, Turkey). Half - dose of recombinant tissue-type plasminogen activator in the treatment of acute pulmonary embolism: long term outcomes. 565
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Soluble urokinase-type plasminogen activator receptor in monitoring of treatment response in acute exacerbation of chronic obstructive pulmonary disease
Source: International Congress 2017 – Current challenges in COPD evaluation
Year: 2017
Observational study of the use of recombinant tissue-type plasminogen activator in COVID-19 shows a decrease in physiological dead space
Source: ERJ Open Res, 6 (4) 00455-2020; 10.1183/23120541.00455-2020
Year: 2020
Efficacy of thrombolytic agents in the treatment of pulmonary embolism
Source: Eur Respir J 2005; 26: 864-874
Year: 2005
The biological effect of intrapleural tissue plasminogen (tPA) activator and DNase delivery in pleural infection patients.
Source: International Congress 2018 – New therapies for respiratory infections: experimental and translational studies
Year: 2018
Soluble urokinase plasminogen activator receptor (suPAR) predicts mortality in exacerbated COPD
Source: International Congress 2018 – New predictors of morbidity and mortality in COPD
Year: 2018
Pro-urokinase up-regulates the expression of urokinase type plasminogen activator (u-PA) in human pulmonary arterial endothelial cells
Source: Eur Respir J 2007; 30: Suppl. 51, 143s
Year: 2007
The relation between plasminogen activator inhibitor-1 (PAI-1) and inflammatory markers in COPD: A possible risk factor of inflammation-induced thrombosis
Source: International Congress 2017 – Systemic and airway biomarkers
Year: 2017
Upregulation of the gene encoding the urokinase-type plasminogen activator (uPA) in respiratory muscles of COPD patients
Source: Annual Congress 2004 - Skeletal muscle in respiratory disease
Year: 2004
Soluble urokinase plasminogen activator receptor (suPAR) is associated with COPD readmission and mortality
Source: International Congress 2019 – Long-term lung function: from early birth to adulthood
Year: 2019
Comparison of intrapleural use of urokinase and tissue plasminogen activator/DNAse in pleural infection
Source: ERJ Open Res, 5 (3) 00084-2019; 10.1183/23120541.00084-2019
Year: 2019
Soluble urokinase-type plasminogen activator receptor is a novel biomarker predicting acute exacerbation in COPD
Source: International Congress 2015 – Non-exhaled biomarkers in the assessment of airways disease
Year: 2015
Suppression of plasminogen activator inhibitor-1 by RNA interference attenuates pulmonary fibrosis
Source: Annual Congress 2010 - Experimental approaches in pulmonary fibrosis
Year: 2010
Intrapleural use of dornase alfa and tissue plasminogen activator are successful as treatment in pediatric empyema: a pilot study
Source: International Congress 2018 – Paediatric respiratory infections: mechanistic insights and clinical outcomes
Year: 2018
Soluble urokinase plasminogen activator receptor for the prediction of ventilator-associated pneumonia
Source: ERJ Open Res, 5 (1) 00212-2018; 10.1183/23120541.00212-2018
Year: 2019
Outcomes of intrapleural tissue plasminogen activator (tPA) and deoxyribnuclease (DNase) for IPC-related pleural infection
Source: International Congress 2019 – Pleural infection and complicated pneumonia
Year: 2019
Intra-airway administration of small interfering RNA targeting plasminogen activator inhibitor-1 suppresses allergic asthma in a murine model
Source: Annual Congress 2010 - Animal models of asthma and lung inflammation
Year: 2010
Enoxaparin reduced ventilation-induced plasminogen activator inhibitor-1
Source: Annual Congress 2009 - Crossing the line: alveolo-capillary barrier control in acute lung injury
Year: 2009
Urokinase plasminogen activator receptor polymorphisms and airway remodelling in asthma
Source: Eur Respir J 2016; 47:1568-1571
Year: 2016
The regulation of plasminogen activator inhibitor-1 (PAI-1) production with dexamethasone by human lung fibroblasts
Source: Eur Respir J 2005; 26: Suppl. 49, 343s
Year: 2005
Urokinase type plasminogen activator improves airway inflammation and mucin expression in a murine asthma model
Source: Annual Congress 2010 - Mechanisms and modulation of allergic inflammation in the lung
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept